Skip to main content

#153634

Anti-Follistatin 288 [17-2]

Cat. #153634

Anti-Follistatin 288 [17-2]

Cat. #: 153634

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Follistation 288

Class: Monoclonal

Application: ELISA ; IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: BioServ UK Ltd

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Follistatin 288 [17-2]
  • Alternate name: Follistatin, FS, FST, Active-binding protein
  • Research fields: Cancer;Cell signaling and signal transduction;Genetics;Immunology;Neurobiology
  • Clone: 15
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 37 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; WB
  • Description: Follistatin is a single-chain glycosylated protein that inhibits follicle stimulating hormone (FSH) release. Alternative splicing of Follistatin mRNA yields two isoforms, FS315 and FS288. FS288 is the main cell-surface form and binds to surface heparin sulphate proteoglycans. Clone 17/2 recognizes recombinant human Follistatin 288, allowing for detection of FSH levels using various analysis methods. This antibody also works in a two site ELISA with Clone 29/9.
  • Immunogen: Recognizes human Follistatin isoform FS288, raised against recombinant human FS288
  • Isotype: IgG1
  • Myeloma used: Sp2/0-Ag14
  • Recommended controls: Testis

Target Details

  • Target: Follistation 288
  • Molecular weight: 37 kDa
  • Tissue cell line specificity: Testis
  • Target background: Follistatin is a single-chain glycosylated protein that inhibits follicle stimulating hormone (FSH) release. Alternative splicing of Follistatin mRNA yields two isoforms, FS315 and FS288. FS288 is the main cell-surface form and binds to surface heparin sulphate proteoglycans. Clone 17/2 recognizes recombinant human Follistatin 288, allowing for detection of FSH levels using various analysis methods. This antibody also works in a two site ELISA with Clone 29/9.

Applications

  • Application: ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Hands et al. 2013. Anal Bioanal Chem. 405(23):7347-55. PMID: 23831829.
  • Investigating the rapid diagnosis of gliomas from serum samples using infrared spectroscopy and cytokine and angiogenesis factors.
  • Fitzgerald et al. 2012. Invest Ophthalmol Vis Sci. 53(11):7358-69. PMID: 23010638.
  • The effects of transforming growth factor-?2 on the expression of follistatin and activin A in normal and glaucomatous human trabecular meshwork cells and tissues.
  • Mabuchi et al. 2006. Oncol Rep. 15(2):291-6. PMID: 16391844.
  • Immunohistochemical localization of inhibin and activin subunits, activin receptors, and Smads in ovarian clear cell adenocarcinoma.
  • Pratic et al. 2004. Chem Phys Lipids. 128(1-2):165-71. PMID: 15037161.
  • F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases.
  • Evans et al. 1998. J Endocrinol. 156(2):275-82. PMID: 9518873.
  • Development, validation and application of an ultra-sensitive two-site enzyme immunoassay for human follistatin.
  • Majdic et al. 1997. Endocrinology. 138(5):2136-47. PMID: 9112414.
  • Testicular expression of inhibin and activin subunits and follistatin in the rat and human fetus and neonate and during postnatal development in the rat.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.